/Agilent%20Technologies%20Inc_%20HQ%20sign-by%20hapabapa%20via%20iStock.jpg)
Santa Clara, California-based Agilent Technologies, Inc. (A) is a global leader in providing application-focused solutions to the life sciences, diagnostics, and applied chemical markets. Valued at a market cap of $33.9 billion, the company designs and manufactures a broad portfolio of analytical instruments, software, consumables, and services. It is scheduled to announce its fiscal Q3 earnings for 2025 after the market closes on Wednesday, Aug. 27.
Before this event, analysts project this healthcare company to report a profit of $1.37 per share, up 3.8% from $1.32 per share in the year-ago quarter. The company has surpassed Wall Street’s bottom-line estimates in each of the last four quarters. Its earnings of $1.31 per share in the previous quarter outpaced the consensus estimates by 4%.
For the full year, analysts expect A to report EPS of $5.59, up 5.7% from $5.29 per share in fiscal 2024. Furthermore, its EPS is expected to grow 8.8% year-over-year to $6.08 in fiscal 2026.
A has fallen 8.6% over the past 52 weeks, underperforming both the S&P 500 Index's ($SPX) 14.5% return and the Health Care Select Sector SPDR Fund’s (XLV) 8.3% loss over the same time frame.
Agilent Technologies reported impressive Q2 performance on May 28, and its shares surged 2.2% in the following trading session. Due to growth in its life sciences and diagnostics markets revenue and a rise in CrossLab segment’s sales, the company's overall revenue improved 6% year-over-year to $1.7 billion, topping consensus estimates by 2.5%. Moreover, its adjusted EPS of $1.31 advanced 7.4% from the prior-year quarter, exceeding Wall Street expectations by 4%. A’s effective Ignite Transformation initiative supported its Q2 results.
Looking ahead to fiscal 2025, A expects revenue to range between $6.7 and $6.8 billion, and projects adjusted EPS in the range of $5.54 to $5.61.
Wall Street analysts are moderately optimistic about A’s stock, with an overall "Moderate Buy" rating. Among 16 analysts covering the stock, eight recommend "Strong Buy," and eight advise “Hold.” The mean price target for A is $138.57, indicating a 16% premium from the current levels.
